Global Anticoagulants Market Growth (Status and Outlook) 2023-2029

Global Anticoagulants Market Growth (Status and Outlook) 2023-2029

Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help keep the bite area unclotted long enough for the animal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used in hospitals. Some anticoagulants are used in medical equipment, such as test tubes, serum-separating tubes, blood transfusion bags, and dialysis equipment.

LPI (LP Information)' newest research report, the “Anticoagulants Industry Forecast” looks at past sales and reviews total world Anticoagulants sales in 2022, providing a comprehensive analysis by region and market sector of projected Anticoagulants sales for 2023 through 2029. With Anticoagulants sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anticoagulants industry.

This Insight Report provides a comprehensive analysis of the global Anticoagulants landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Anticoagulants portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anticoagulants market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anticoagulants and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anticoagulants.

The global Anticoagulants market size is projected to grow from US$ 25390 million in 2022 to US$ 35420 million in 2029; it is expected to grow at a CAGR of 4.9% from 2023 to 2029.

Market competition is intense. Sanofi, Bristol-Myers Squibb, Bayer, Johnson & Johnson, Genentech (Roche) and Boehringer Ingelheim etc. are the leaders of the industry, with about 64% market shares.

North America is the largest consumption place, with a consumption market share nearly 39%. Following North America, Europe is the second largest consumption place with the consumption market share of 26%.

This report presents a comprehensive overview, market shares, and growth opportunities of Anticoagulants market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

Platelet Aggregation Inhibitors (PAI)

Low-Molecular-Weight Heparin (LMWH)

Direct Thrombin Inhibitor (DTI)

Direct Factor Xa Inhibitors (DFXa)

Vitamin K antagonists (VKA)

Others

Segmentation by application

VTE

ACS/MI

AF

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Sanofi

Bristol-Myers Squibb

Bayer

Johnson & Johnson.

Genentech (Roche)

Boehringer Ingelheim

Lilly

Daiichi Sankyo

Otsuka

AstraZeneca

Pfizer

Aspen

The Medicines Company

Please note: The report will take approximately 2 business days to prepare and deliver.